Oatly Group AB - ADR vs GeneDx Holdings Corp — how do they compare? Oatly Group AB - ADR trades at $10.86 (market cap $282.27M), while GeneDx Holdings Corp trades at $61.39 (market cap $1.83B). The key difference: GeneDx Holdings Corp is far larger — about 6.5× Oatly Group AB - ADR's market cap. Which is the better fit depends on your goals.
| OTLY | WGS | |
|---|---|---|
Market Cap | $282.27M | $1.83B |
Sector | Consumer Staples | Technology |
52-Week High | $18.54 | $167.51 |
52-Week Low | $8.03 | $34.51 |
Enterprise Value | $779.89M | $1.83B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% today, amid a bearish technical signal and multiple class-action lawsuits alleging securities fraud. The stock shows weak fundamentals with a negative net income margin of -17.58% and ROE of -30.42%, though it beat EPS estimates in two of the last three quarters. Revenue grew to $427.54M in 2025 but profitability remains a challenge, with a high EV/EBITDA of 161.17 indicating stretched valuation relative to earnings.
Despite a 90.9% analyst buy rating and a $75.40 consensus price target, significant risks from litigation and persistent losses cloud the outlook. The stock faces near-term pressure from legal overhangs, while operational cash flow turned negative in 2026. Investors should weigh high analyst optimism against substantial fundamental and legal headwinds before considering a position.
Trailing returns across standard periods
Latest headlines on both assets
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →